Deals this week: Diaxonhit SA, Trovagene, Avizia

14 July 2016 (Last Updated July 14th, 2016 18:30)

Diaxonhit SA, a specialty diagnostic solutions provider, has signed an exclusive distribution agreement in France with Advanced Biological Laboratories (ABL), a medical data technology company.

Diaxonhit SA, a specialty diagnostic solutions provider, has signed an exclusive distribution agreement in France with Advanced Biological Laboratories (ABL), a medical data technology company.

Pursuant to the agreement, the former will get exclusive distribution rights of the latter’s reactive DeepChek Single Round HIV and HCV products, which are used for the genotyping of HIV and hepatitis C (HCV) viruses.

Also included in the agreement, on a non-exclusive basis, is the distribution of ABL-developed software and DeepChek ViroScore, which are used for analysing sequencing platforms from the Sanger and next-generation sequencing (NGS) technologies.

USC Norris Comprehensive Cancer Center has entered a broad collaborative agreement with Trovagene, a developer of circulating tumour DNA (ctDNA) molecular diagnostics, for establishing a standardised framework for the use of Trovera, a urine liquid biopsy test, at USC.

It will also seek to define practical considerations and best practices for liquid biopsy testing from urine. Further, the collaboration will explore the development of clinical treatment algorithms through investigational studies to figure out how and when liquid biopsy testing can be used.

In a the Series A financing round led by Blue Heron Capital, Avizia, a telemedicine company, has raised $11m, which will be used to expand its sales, marketing, technology and management activities.

The financing round has also seen the participation of Lavrock Ventures, NextGen Venture Partners, Middleland Capital, Waterline Capital BV, and Blu Venture Investors.

To improve its commercial operations and to globally launch its sixth-generation product named IMPLEO, GC Aesthetics, an Irish breast implant maker, has raised $20m in a Series D venture financing round.

"Existing investors including Montreux Equity Partners, Oyster Capital Group, and Barry's Tea Holdings have participated in the round."

Existing investors including Montreux Equity Partners, Oyster Capital Group, and Barry's Tea Holdings have participated in the round.

Molecular diagnostics firm Immunarray has received a $10m investment from a Series B financing round led by Exigent Alternative Capital.

The investment will be used by the company to further develop its blood-testing technology for chronic diseases and traumatic head injuries.